0001562180-23-002911.txt : 20230317
0001562180-23-002911.hdr.sgml : 20230317
20230317161056
ACCESSION NUMBER: 0001562180-23-002911
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20230315
FILED AS OF DATE: 20230317
DATE AS OF CHANGE: 20230317
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Umstead John V.
CENTRAL INDEX KEY: 0001967910
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38096
FILM NUMBER: 23742656
MAIL ADDRESS:
STREET 1: C/O G1 THERAPEUTICS, INC.
STREET 2: 700 PARK OFFICES DRIVE, SUITE 200
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: G1 Therapeutics, Inc.
CENTRAL INDEX KEY: 0001560241
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 263648180
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 700 PARK OFFICES DRIVE
STREET 2: SUITE 200
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
BUSINESS PHONE: 919-213-9835
MAIL ADDRESS:
STREET 1: 700 PARK OFFICES DRIVE
STREET 2: SUITE 200
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
FORMER COMPANY:
FORMER CONFORMED NAME: G-Zero Therapeutics, Inc.
DATE OF NAME CHANGE: 20121012
3
1
primarydocument.xml
PRIMARY DOCUMENT
X0206
3
2023-03-15
0
0001560241
G1 Therapeutics, Inc.
GTHX
0001967910
Umstead John V.
700 PARK OFFICES DRIVE, SUITE 200
RESEARCH TRIANGLE PARK
NC
27709
false
true
false
false
Chief Financial Officer
Common Stock
8886.00
D
Stock Options (Right to buy)
41.48
2022-10-22
2028-11-01
Common Stock
10000.00
D
Stock Options (Right to buy)
30.46
2029-07-01
Common Stock
2000.00
D
Stock Options (Right to buy)
21.08
2030-02-06
Common Stock
6600.00
D
Stock Options (Right to buy)
18.07
2031-01-04
Common Stock
2550.00
D
Stock Options (Right to buy)
10.69
2032-01-03
Common Stock
6100.00
D
Stock Options (Right to buy)
5.73
2033-01-03
Common Stock
6000.00
D
Represents (i) 2,036 shares of common stock; (ii) 850 restricted stock units ("RSUs") from award granted on January 4, 2021; (iii) 3,000 RSUs from award granted on January 3, 2022; and (iv) 3,000 RSUs from award granted on January 3, 2023.
The shares underlying this option vest as to 25% of the shares on July 1, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. The option was granted on July 1, 2019.
The shares underlying this option vest as to 25% of the shares on February 6, 2021, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. The option was granted on February 6, 2020.
The shares underlying this option vest as to 25% of the shares on January 4, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. The option was granted on January 4, 2021.
The shares underlying this option vest as to 25% of the shares on January 3, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. The option was granted on January 3, 2022.
The shares underlying this option vest as to 25% of the shares on January 3, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. The option was granted on January 3, 2023.
/s/ James Stillman Hanson, attorney-in-fact
2023-03-17
EX-24
2
jumsteadpoa.txt
POWER OF ATTORNEY
POWER OF ATTORNEY
Know all by these present, that the undersigned hereby
constitutes and appoints each of James Stillman Hanson, General
Counsel, of G1 Therapeutics, Inc. (the "Company"), Sandi James,
Director, Legal, of the Company, and Jason McCaffrey, Raven Sun,
Justin Omalev, Charles Smith, Tanya Sylla, and Brenda Meyette of
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., signing singly,
with full power of substitution, the undersigned's true and lawful
attorney-in-fact to:
(1) execute for and on behalf of the undersigned, forms and
authentication documents for EDGAR Filing Access;
(2) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to
complete and execute any such forms and authentication
documents;
(3) execute for and on behalf of the undersigned, in the
undersigned's capacity as an officer, director and/or 10%
shareholder of the Company, Forms 3, 4 and 5 in accordance
with Section 16(a) of the Securities Exchange Act of 1934
and the rules thereunder;
(4) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to
complete and execute any such Form 3, 4 or 5 and timely
file such form with the United States Securities and
Exchange Commission and any stock exchange or similar
authority; and
(5) take any other action of any type whatsoever in connection
with the foregoing which, in the opinion of such attorney-
in-fact, may be of benefit to, in the best interests of,
or legally required by the undersigned, it being
understood that the documents executed by such attorney-
in-fact on behalf of the undersigned pursuant to this
Power of Attorney shall be in such form and shall contain
such terms and conditions as such attorney-in-fact may
approve in such attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full
power and authority to do and perform any and every act and thing
whatsoever requisite, necessary, or proper to be done in the
exercise of any of the rights and powers herein granted, as fully to
all intents and purposes as the undersigned might or could do if
personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or
such attorney-in-fact's substitute or substitutes, shall lawfully do
or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned acknowledges that
the foregoing attorneys-in-fact, in serving in such capacity at the
request of the undersigned, are not assuming, nor is the Company
assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Securities Exchange Act of 1934, as amended.
This Power of Attorney shall remain in full force and effect
until the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in
securities issued by the Company, unless earlier revoked by the
undersigned in a signed writing delivered to the foregoing attorneys-
in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed on February 28, 2023.
/s/ John Umstead V
Signature
John Umstead V
Print Name